22:45 , Apr 7, 2017 |  BioCentury  |  Finance

To market, to market

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...
20:51 , Mar 23, 2017 |  BC Week In Review  |  Clinical News

AEVI-001: Ph II/III SAGA data

Top-line data from the double-blind, U.S. Phase II/III SAGA trial in 96 evaluable ADHD patients ages 12-17 with genetic disorders impacting mGluRs showed that twice-daily oral AEVI-001 missed the primary endpoint of reducing ADHD-RS total...
22:39 , Mar 20, 2017 |  BC Extra  |  Clinical News

Aevi plummets after ADHD candidate fails in Phase II/III

Aevi Genomic Medicine Inc. (NASDAQ:GNMX) shed $3.23 (59%) to $2.21 on Monday after it said AEVI-001 missed the primary endpoint in the Phase II/III SAGA study to treat ADHD in adolescent patients with metabotropic glutamate...
21:45 , Feb 1, 2017 |  BC Week In Review  |  Clinical News

AEVI-001: Ph I/II started

Aevi began an open-label, U.S. Phase I/II trial evaluating 50, 100, 200 and 400 mg oral AEVI-001 twice daily over 5 weeks in about 12 patients ages 12-17 with a 22q11.2 deletion and diagnosed with...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Clinical News

NFC-1: Phase II/III started

Medgenics began the double-blind, placebo-controlled, U.S. Phase II/III SAGA trial to evaluate 100, 200 and 400 mg oral NFC-1 twice daily for 6 weeks in 90 patients ages 12-17. In 1H17, Medgenics plans to start...
07:00 , Jun 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Metabotropic glutamate receptor subtype 1 (mGluR1; GRM1); SH3 and multiple ankyrin repeat domains 3 (SHANK3; PROSAP2; SPANK-2)

Neurology INDICATION: Autism Mouse studies suggest positive allosteric modulators (PAMs) of mGluR1 could help treat autism spectrum disorders caused by SHANK3 haploinsufficiency. In a mouse model of SHANK3-deficient autism, an mGluR1 PAM increased synaptic transmissions...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Company News

neuroFix Therapeutics, Medgenics deal

Medgenics acquired neuroFix for $2 million in cash and more than $481 million in potential milestones. neuroFix is eligible to receive $6 million in cash and stock upon the earlier of the completion of an...
08:00 , Jan 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Metabotropic glutamate receptor subtype 1 (mGluR1; GRM1)

Neurology INDICATION: Ataxia Mouse studies suggest inhibiting calcium influx in Purkinje neurons could be useful for treating spinocerebellar ataxia type 28 (SCA28). In a mouse model of SCA28, loss-of-function mutations in Grm1 decreased Ca2+ influx...
08:00 , Dec 4, 2014 |  BC Innovations  |  Cover Story

GPCRs' grand plans

In a move to expand tenfold the number of known 3D structures of the highly druggable class of GPCRs, Amgen Inc. , Ono Pharmaceutical Co. Ltd. and Sanofi have teamed up with three academic organizations...
07:00 , Apr 3, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Crystal structure of metabotropic glutamate receptor subtype 1 (mGluR1; GRM1) The crystal structure of mGluR1 could help researchers design mGluR1-targeted therapeutics to treat cancer and...